



Advancing Research. Improving Lives.™

TO: ALL PRINCIPAL INVESTIGATORS, NURSES, AND DATA MANAGERS

FROM: NRG-DT001 Study Chair
Meng Welliver, MD, PhD

DATE: April 28, 2020

RE: PROTOCOL NRG-DT001 – Cohort B: Reopening to Accrual to Dose Level 2

Cohort B Reopening to Accrual to Dose Level 2

Cohort B (abdomen/pelvis/retroperitoneum) of NRG-DT001, “A Phase IB Trial of Neoadjuvant AMG 232 Concurrent with Preoperative Radiotherapy in Wild-Type p53 Soft Tissue Sarcoma (STS),” is reopened to accrual to dose level 2 effective immediately.

Cohort B will remain open to accrual until 3 wild-type p53 patients have been enrolled to dose level 2. A broadcast with more details regarding accrual closure will be sent when the target accrual has been reached.

Note: Dose level 3 for cohort A (extremity/body wall) remains open to accrual.

Please distribute this information to the appropriate personnel.

A handwritten signature in blue ink that reads "Meng Welliver".

Meng Welliver, MD, PhD